Primary information |
---|
ID | 1032 |
Peptide Name | [K16,D20,Y36]-OSK1 |
Sequence | GVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCYPK |
Length | 38 |
Chirality | L |
N-terminal Modification | None |
C-terminal Modification | None |
Chemical Modification | Three- Disulphide-bridge (C1-C4, C2-C5 and C3-C6) |
Linear/ Cyclic | Linear |
Nature | Synthetic |
Source of Origin | NA |
Target | Kv 1.1, Kv 1.2, Kv 1.3 and Kv 1.7 channel and also Ca2+ -activated KCa 3.1 channel |
Mechanism of Action | Blocker of four different Kv channel types and also blocker of Ca2+ -activated KCa 3.1 channel |
In vitro/In vivo | Both |
Cell Line | L929 and MEL (murine erythroleukaemia), COS-7 cells, tsA cell line, LTK-cells (lacking leucocyte tyrosine kinase), CHL (Chinese-hamster lung) cells, HEK-293 (human embryonic kidney) cells |
Inhibition Concentartion | 232±11 nM for Kv1.2 |
In vivo Model | C57/BL6 mice |
Assay | Neurotoxicity of peptide, Pharmacological activity on various K+ (Potassium) channel |
Lethal Dose | 9 (μg/kg of mice) |
Combination Therapy | NA |
Pubmed ID | 15588251 |
Year of Publication | 2005 |
3-D Structure | NA |